Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Lineage Commitment01:21

Lineage Commitment

4.5K
Commitment is the  process whereby stem cells:
4.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.

American journal of hematology·2026
Same author

Serum Metabolomic Signatures Indicate Oxidative Membrane Lipid Remodeling in β-Thalassemia.

Metabolites·2026
Same author

The Role of microRNAs as Potential Biomarkers in Diffuse Large B-Cell Lymphoma.

Non-coding RNA·2026
Same author

The Use of Enhanced Analytical Pipelines for the Characterization of Poly(A) and Poly(A)-LNP Formulation Critical Quality Attributes.

Molecular pharmaceutics·2025
Same author

Applications of Multiparameter Flow Cytometry in the Diagnosis, Prognosis, and Monitoring of Multiple Myeloma Patients.

Diseases (Basel, Switzerland)·2025
Same author

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies.

Diseases (Basel, Switzerland)·2025

相关实验视频

Updated: Feb 27, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.8K

在AML中解码白血病干细胞:从识别到有针对性的根除

Elisavet Apostolidou1, Vasileios Georgoulis1, Dimitrios Leonardos1

  • 1Department of Haematology, University Hospital of Ioannina, 45 500 Ioannina, Greece.

Diseases (Basel, Switzerland)
|February 26, 2026
PubMed
概括
此摘要是机器生成的。

白血病干细胞 (LSCs) 驱动急性髓性白血病 (AML) 复发. 了解LSC生物学和向这些耐治疗细胞对于改善AML治疗结果和预防疾病复发至关重要.

关键词:
急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.免疫类型 免疫类型白血病干细胞是白血病的干细胞有针对性的治疗.

更多相关视频

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.8K
Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

4.8K

相关实验视频

Last Updated: Feb 27, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.8K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.8K
Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

4.8K

科学领域:

  • 血液学 血液学 血液学
  • 癌症生物学 癌症生物学
  • 干细胞研究 干细胞研究

背景情况:

  • 由于复发率高,急性髓性白血病 (AML) 存在重大治疗挑战.
  • 白血病干细胞 (LSCs) 是一种罕见的,耐治疗的群体,负责疾病的重新开始和复发.

研究的目的:

  • 审查LSC生物学最近的进展,重点关注与正常造血干细胞 (HSC) 的功能和表型差异.
  • 讨论LSC量化方法,潜在的分子程序以及当前/新兴的治疗策略.
  • 检查转化障碍,并提出将LSC评估纳入临床实践的框架.

主要方法:

  • 目前关于LSC生物学,功能和治疗向的文献综合.
  • 讨论多参数流细胞计和标记面板用于LSC量化.
  • 对LSC中信号传递,代谢和表观遗传失调的审查.

主要成果:

  • 与HSC相比,LSC表现出不同的功能和表型特征.
  • 调节失调的细胞程序有助于LSC的持续性和可测量的残留疾病.
  • 目前正在研究针对LSC的各种治疗策略,以及已识别的转化障碍.

结论:

  • 针对LSC是克服AML治疗挑战和降低复发率的关键.
  • 需要进一步的研究和测试协调,以有效地将LSC评估纳入AML管理.
  • 开发新的LSC导向疗法有望改善AML患者的治疗结果.